Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody (Epcoritamab, RUO) (HY257136)

Name: Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody (Epcoritamab, RUO)
Brand: abinScience
SKU: HY257136
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HY257136
Description	Research Grade Epcoritamab (HY257136) is a chimeric monoclonal antibody detecting B-lymphocyte surface antigen B1 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human. Highlights ●Multi-Application — Validated across multiple applications.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôte	Chimeric
Clonalité	Monoclonal
Isotype	Ig(G1-kappa_G1-lambda)
Applications testées	WB
Cible	B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, CD20, Leukocyte surface antigen Leu-16, MS4A1, Membrane-spanning 4-domains subfamily A member 1, CD3E, CD3e, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 epsilon chain, T3E
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P11836 & P07766
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	GEN3013, 2134641-34-0
Contexte	Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

Detects CD3E in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody (Epcoritamab, RUO)
Western blot

Western blot analysis was performed using anti-CD3E monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD3E (Catalog No: HY057011)
Lane 2: negative control